Genedata
Genedata is a Swiss bioinformatics company providing enterprise software for biopharmaceutical research, development, characterization, and manufacturing.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Genedata is a Basel-based bioinformatics and scientific software company founded in 1997 by Othmar Pfannes. It develops enterprise platforms intended to help biopharmaceutical companies, biotechnology firms, and research institutions manage, analyze, and operationalize complex scientific data across the drug-development lifecycle. Its software is positioned between scientific informatics, laboratory and process data management, workflow automation, and advanced analytics. The company began developing software for drug-target discovery and introduced its first product in 1998. Over time, it expanded from discovery-oriented bioinformatics into a broader portfolio supporting biotherapeutic research and development. Its Genedata Biopharma Platform is modular: organizations can deploy individual applications for specific workflows or connect multiple systems to link data across discovery, development, translational research, quality control, and manufacturing. This approach is designed to reduce fragmented data environments and improve the reuse, traceability, and consistency of scientific information. Genedata's software supports research involving a range of therapeutic modalities, including antibodies, cell and gene therapies, RNA-based products, and vaccines. Its applications cover assay-data management, mass-spectrometry characterization, next-generation sequencing, biologics discovery, translational research, bioprocess development, chromatography, and chemistry, manufacturing, and controls data. The company emphasizes digitalization, workflow automation, data FAIRness, artificial intelligence, and adherence to regulatory expectations as biopharmaceutical development becomes more data-intensive and distributed. Genedata operates from Basel and has additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo. Its presence in major biopharmaceutical and technology clusters supports work with multinational pharmaceutical companies, emerging biotechnology companies, and scientific institutions. According to the referenced company description, approximately 500 employees work across the organization, and the customer base includes many of the world's largest biopharmaceutical enterprises. In July 2024, Genedata joined the Danaher Group. The transaction placed Genedata within a larger life-sciences and diagnostics-oriented corporate environment while preserving its identity as a specialist provider of scientific informatics software. Genedata remains an active business focused on connecting scientific data and workflows across biopharmaceutical research, development, and manufacturing.
History
Genedata was established in Basel, Switzerland, in 1997 by Othmar Pfannes. It entered the market as a bioinformatics company serving the information and analysis needs of drug research. Its first product, developed for drug-target discovery, was introduced in 1998. This initial focus placed Genedata in a field where pharmaceutical research was producing increasingly large and complex datasets but still relied heavily on disconnected specialist tools and manual interpretation. The company subsequently broadened its scope from target-discovery software to an enterprise platform for biopharmaceutical research and development. Its product portfolio grew to address multiple scientific and operational stages, including assay analysis, biologics discovery, mass-spectrometry characterization, sequencing, translational research, bioprocess development, chromatography, and quality control. Rather than limiting its systems to one modality or one laboratory function, Genedata developed modular applications that could be used independently or combined to connect data streams between development groups. This expansion reflected changes in the biopharmaceutical industry. Drug developers increasingly needed to coordinate experimental data, analytical results, process information, and regulatory documentation across geographically distributed teams. Genedata's software strategy therefore emphasized workflow standardization, automation, data integration, FAIR data principles, and analytics, including artificial-intelligence-enabled analysis in selected areas. The platform came to support work on antibodies and other biologics as well as newer modalities such as cell and gene therapies, RNA products, and vaccines. Genedata developed an international operating footprint around major life-sciences centers. In addition to its Basel headquarters, it established offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo. Its customers include large biopharmaceutical enterprises, biotechnology companies, and research institutions. The company's stated customer base includes many of the world's largest biopharmaceutical organizations, and its workforce grew to approximately 500 employees according to the referenced company material. A major corporate turning point came in July 2024, when Genedata joined the Danaher Group. The combination aligned Genedata's specialist scientific-informatics capabilities with Danaher's wider life-sciences businesses. Genedata continues to operate as an active provider of software for biopharmaceutical discovery, development, characterization, translational research, bioprocessing, and manufacturing-related workflows.
- 2024
Joins Danaher
[1]In July 2024, Genedata became part of the Danaher Group.
- 1998
First drug-target discovery product
[1]Genedata developed and released its first product for drug-target discovery, establishing its initial product focus in pharmaceutical research informatics.
- 1997
Genedata is founded
[1]Othmar Pfannes founded Genedata in Basel, Switzerland, as a company focused on bioinformatics and software for life-sciences research.
Products and positioning
A specialist enterprise-software provider for biopharmaceutical science, positioned around connected scientific workflows, data integration, automation, FAIR data practices, regulatory readiness, and analytics across discovery through manufacturing.
Assay data analytics and management
Genedata Screener
Genedata Screener supports the management and analysis of assay data used in discovery and development. It is intended to help research organizations organize experimental results, apply consistent analytical workflows, and turn screening data into information usable by scientific teams across projects.
Mass-spectrometry data analysis
Genedata Expressionist
Genedata Expressionist is designed for mass-spectrometry-based characterization and quality control of biotherapeutics. It supports analytical workflows in which developers need to examine complex molecular data and connect characterization results with broader development and quality processes.
Next-generation sequencing bioinformatics
Genedata Selector
Genedata Selector provides workflows for next-generation sequencing applications, including target discovery, bioprocess development, and quality control of biotherapeutics. It is intended to help organizations manage sequencing-derived information within reproducible and industrialized research processes.
Biotherapeutics discovery
Genedata Biologics
Genedata Biologics covers end-to-end biotherapeutic discovery workflows across multiple modalities. The system is positioned for organizations that need to connect discovery activities, scientific data, and decision-making processes rather than manage each stage through isolated tools.
Translational research and precision medicine
Genedata Profiler
Genedata Profiler supports translational research and precision-medicine development. It is intended to help research teams bring together complex biological and clinical information so that findings can be evaluated across the boundary between laboratory research and development activities.
Bioprocess development
Genedata Bioprocess
Genedata Bioprocess supports workflows for bioprocess development. Its role is to organize and analyze process-related information, helping development teams connect experimental work with process understanding, comparison, and optimization.
Chromatography data management
Genedata Chromatics
Genedata Chromatics is intended to streamline chromatography data management and analysis. It addresses the handling of chromatography results within biopharmaceutical development and quality workflows, where consistent interpretation and traceable data are important.
CMC data and artificial-intelligence analytics
Genedata Vico
Genedata Vico provides unified chemistry, manufacturing, and controls data capabilities with AI-driven analytics across development and manufacturing. It is positioned to help organizations connect CMC information and use advanced analysis in operational and technical decision-making.
Brand decisions
2024
Integration into the Danaher GroupM&ABackground
Genedata had developed an international software business serving biopharmaceutical research and development, with a portfolio spanning discovery, analytical characterization, translational research, bioprocessing, and manufacturing-related workflows.
Action taken
In July 2024, Genedata joined the Danaher Group.
Aftermath
Genedata continued as an active specialist provider of biopharmaceutical informatics software within Danaher's life-sciences environment. Detailed transaction terms and financial effects are not provided in the available reference material.
Recent events
Genedata launches integrated electronic lab notebook[2]
Reported:
Genedata launched an electronic lab notebook integrated directly into its platform, connecting experimental context with scientific data across biopharmaceutical discovery and development workflows.
Genedata launches Biomarker Discovery Agent in Genedata Profiler[3]
Reported:
Genedata, a Danaher company, announced a new AI agent in Genedata Profiler, its enterprise platform for integrating and analyzing translational and clinical research data, expanding AI-driven biomarker discovery capabilities. In collaboration with Washington University School of Medicine in St. Louis, the agent was used to identify a five-protein blood-based model for Alzheimer's disease validated in an independent cohort.
Genedata Selector becomes available for TLA data analysis[4]
Reported:
Genedata announced the availability of Genedata Selector for automating the Targeted Locus Amplification data analysis workflow.
Genedata and Cergentis collaborate on TLA workflow automation[4]
Reported:
Genedata said its Selector software solution was developed through close collaboration with Cergentis and joint customers to automate the TLA data analysis workflow.
Genedata and Boehringer Ingelheim expand collaboration[5]
Reported:
Genedata announced an expansion of its collaboration with Boehringer Ingelheim to digitalize and automate cell line development processes. Genedata Selector was deployed as part of the collaboration.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/genedata · Editorial policy · How profiles are compiled